



## Rhythm Pharmaceuticals to Host Key Opinion Leader Symposium on MC4R Pathway and Patient Experience with Rare Genetic Disorders of Obesity, Including Bardet-Biedl Syndrome

December 6, 2018

BOSTON, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that it will host a key opinion leader symposium on the melanocortin-4 receptor (MC4R) pathway and patient experience with rare genetic disorders of obesity, with a particular focus on Bardet-Biedl Syndrome (BBS). The event will be held on Thursday, December 13, 2018 from 8:30 a.m. to 10:00 a.m. ET in New York.

Guest speakers scheduled to present at the event include:

- **Bob Haws, M.D.**, Director of Clinical Research at the Marshfield Clinic Research Institute and Director of the Center of Excellence for Bardet-Biedl Syndrome
- **Lee Kaplan, M.D., Ph.D.**, Director of the Obesity, Metabolism & Nutrition Institute at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School

Additionally, Rhythm management will provide an overview of its clinical development program for setmelanotide, focusing on its combined pivotal Phase 3 trial in BBS and Alström Syndrome, which is expected to initiate and begin enrolling patients by year-end 2018.

A live audio webcast of the event will be available under "Events & Presentations" in the Investors & Media section of the Company's website at [www.rhythmtx.com](http://www.rhythmtx.com). A replay of the webcast will be available on the Rhythm website for 30 days following the event.

### About Rhythm

Rhythm is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. Rhythm is currently evaluating the efficacy and safety of setmelanotide, the Company's first-in-class melanocortin-4 receptor (MC4R) agonist, in Phase 3 studies in patients with pro-opiomelanocortin (POMC) deficiency obesity (which includes deficiencies in both the POMC and PCSK1 genes) and leptin receptor (LEPR) deficiency obesity. Rhythm is dedicated to improving the understanding of severe obesity that results from specific genetic disorders. For healthcare professionals, visit [www.uncommonobesity.com](http://www.uncommonobesity.com) for more information. For patients and caregivers, visit [www.geneticobesity.com](http://www.geneticobesity.com) for more information. The company is based in Boston, MA.

### Investor Contact:

Hannah Deresiewicz  
Stern Investor Relations, Inc.  
212-362-1200  
[hannahd@sternir.com](mailto:hannahd@sternir.com)

### Media Contact:

Adam Daley  
Berry & Company Public Relations  
212-253-8881  
[adaley@berrypr.com](mailto:adaley@berrypr.com)



Rhythm Pharmaceuticals, Inc.